Nearly a year after receiving approval from the U.S. Food and Drug
Administration, a new obesity drug will be available to certain patients
by prescription, starting Tuesday. The FDA approved Belviq,
an oral medication, in June 2012. The delay in availability was in part
because the Drug Enforcement Administration needed to review the drug. People with a body mass
index of more than 30 or a BMI of 27 with at least one weight-related
condition, such as hypertension or Type 2 diabetes, are eligible for a
prescription. Belviq, as the FDA pointed out in its statement announcing approval last year, is intended "as an addition to a reduced-calorie diet and exercise."
Belviq, or lorcaserin
hydrochloride, works by activating a serotonin receptor in the brain,
which may help a person eat less and feel full after eating smaller
amounts of food, according to the FDA. Belviq received approval about the same time as another weight-loss pill, Qsymia, which hit the market in September.
More on this story here.
At the bottom of this article I read this. "It is not known if Belviq changes your risk of heart problems or of
stroke, or death due to heart problems or stroke," according to the
drug's website."
My advice is stay well clear of this drug, at least until the manufacturers have worked out whether it will kill you ! Just a thought.
Eddie
No comments:
Post a Comment